Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Viruses
2.3. Number of ADV, HSV-1/2, EBV, CMV, BKV and JCV Virus Copies in Renal Tumor Tissue
2.4. Number of EBV and ADV Virus Copies in Plasma
2.5. Calculation of Viral Load
- human adenovirus (ADV): 500, 5000, 50,000, 500,000 cp/mL,
- herpes simplex virus-1 (HSV-1): 2, 20, 200, 2000 cp/µL,
- herpes simplex virus-2 (HSV-2): 2, 20, 200, 2000 cp/µL,
- Epstein-Barr virus (EBV): 10, 100, 1000, 10,000 cp/µL,
- cytomegalovirus (CMV): 10, 100, 1000, 10,000 cp/µL,
- BK virus (BKV): 10, 100, 1000, 10,000 cp/µL,
- John Cunningham virus (JCV): 10, 100, 1000, 10,000 cp/µL.
2.6. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed]
- Moch, H.; Cubilla, A.L.; Humphrey, P.A.; Reuter, V.E.; Ulbright, T.M. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur. Urol. 2016, 70, 93–105. [Google Scholar] [CrossRef] [PubMed]
- Hidayat, K.; Du, X.; Zou, S.Y.; Shi, B.M. Blood pressure and kidney cancer risk: Meta-analysis of prospective studies. J. Hypertens. 2017, 35, 1333–1344. [Google Scholar] [CrossRef] [PubMed]
- Cumberbatch, M.G.; Rota, M.; Catto, J.W.; La Vecchia, C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur. Urol. 2016, 70, 458–466. [Google Scholar] [CrossRef]
- Gild, P.; Ehdaie, B.; Kluth, L.A. Effect of obesity on bladder cancer and renal cell carcinoma incidence and survival. Curr. Opin. Urol. 2017, 27, 409–414. [Google Scholar] [CrossRef]
- Huang, K.L.; Mashl, R.J.; Wu, Y.; Ritter, D.I.; Wang, J.; Oh, C.; Paczkowska, M.; Reynolds, S.; Wyczalkowski, M.A.; Oak, N.; et al. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell 2018, 173, 355–370. [Google Scholar] [CrossRef]
- Brugarolas, J. Molecular genetics of clear-cell renal cell carcinoma. J. Clin. Oncol. 2014, 32, 1968–1976. [Google Scholar] [CrossRef]
- Pisani, P.; Parkin, D.M.; Muñoz, N.; Ferlay, J. Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomark. Prev. 1997, 6, 387–400. [Google Scholar]
- Alibek, K.; Karatayeva, N.; Bekniyazov, I. The role of infectious agents in urogenital cancers. Infect. Agent Cancer 2012, 7, 35. [Google Scholar] [CrossRef]
- Cai, T.; Di Vico, T.; Durante, J.; Tognarelli, A.; Bartoletti, R. Human papilloma virus and genitourinary cancers: A narrative review. Minerva Urol. Nefrol. 2018, 70, 579–587. [Google Scholar] [CrossRef]
- Li, N.; Yang, L.; Zhang, Y.; Zhao, P.; Zheng, T.; Dai, M. Human papillomavirus infection and bladder cancer risk: A meta-analysis. J. Infect. Dis. 2011, 204, 217–223. [Google Scholar] [CrossRef] [PubMed]
- Jørgensen, K.R.; Jensen, J.B. Human papillomavirus and urinary bladder cancer revisited. APMIS 2020, 128, 72–79. [Google Scholar] [CrossRef] [PubMed]
- Shen, C.H.; Wu, J.D.; Hsu, C.D.; Jou, Y.; Lin, C.; Wang, M.; Wu, S.; Chan, M.W.Y.; Chiang, M.; Fang, C.; et al. The high incidence of JC virus infection in urothelial carcinoma tissue in Taiwan. J. Med. Virol. 2011, 83, 2191–2199. [Google Scholar] [CrossRef]
- Geetha, D.; Tong, B.C.; Racusen, L.; Markowitz, J.S.; Westra, W.H. Bladder carcinoma in a transplant recipient: Evidence to implicate the BK human polyomavirus as a causal transforming agent. Transplantation 2002, 73, 1933–1936. [Google Scholar] [CrossRef] [PubMed]
- Zapatka, M.; Borozan, I.; Brewer, D.S.; Murat Iskar, A.G.; Iskar, M.; Grundhoff, A.; Alawi, M.; Desai, N.; Sültmann, H.; Moch, H.; et al. The landscape of viral associations in human cancers. Nat. Genet. 2020, 52, 320–330. [Google Scholar] [CrossRef] [PubMed]
- Yin, B.; Liu, W.; Yu, P.; Liu, C.; Chen, Y.; Duan, X.; Liao, Z.; Chen, Y.; Wang, X.; Pan, X.; et al. Association between human papillomavirus and prostate cancer: A meta-analysis. Oncol. Lett. 2017, 14, 1855–1865. [Google Scholar] [CrossRef]
- Russo, G.I.; Calogero, A.E.; Condorelli, R.A.; Scalia, G.; Morgia, G.; La Vignera, S. Human papillomavirus and risk of prostate cancer: A systematic review and meta-analysis. Aging Male 2020, 23, 132–138. [Google Scholar] [CrossRef] [PubMed]
- Garolla, A.; Vitagliano, A.; Muscianisi, F.; Valente, U.; Ghezzi, M.; Andrisani, A.; Ambrosini, G.; Foresta, C. Role of Viral Infections in Testicular Cancer Etiology: Evidence from a Systematic Review and Meta-Analysis. Front. Endocrinol. 2019, 10, 355. [Google Scholar] [CrossRef]
- Strickler, H.D.; Schiffman, M.H.; Shah, K.V.; Rabkin, C.S.; Schiller, J.T.; Wacholder, S.; Clayman, B.; Viscidi, R.P. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur. J. Cancer Prev. 1998, 7, 305–313. [Google Scholar] [CrossRef]
- Kim, K.H.; Han, E.M.; Lee, E.S.; Park, H.S.; Kim, I.; Kim, Y.S. Epstein-Barr virus infection in sarcomatoid renal cell carcinoma tissues. BJU Int. 2005, 96, 547–552. [Google Scholar] [CrossRef]
- Shimakage, M.; Kawahara, K.; Harada, S.; Sasagawa, T.; Shinka, T.; Oka, T. Expression of Epstein-Barr virus in renal cell carcinoma. Oncol. Rep. 2007, 18, 41–46. [Google Scholar] [CrossRef] [PubMed]
- Salehipoor, M.; Khezri, A.; Behzad-Behbahani, A.; Geramizadeh, B.; Rahsaz, M.; Aghdaei, M.; Afrasiabi, M.A. Role of viruses in renal cell carcinoma. Saudi J. Kidney Dis. Transpl. 2012, 23, 53–57. [Google Scholar] [PubMed]
- Heim, A.; Ebnet, C.; Harste, G.; Pring-Akerblom, P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J. Med. Virol. 2003, 70, 228–239. [Google Scholar] [CrossRef] [PubMed]
- Lion, T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin. Microbiol. Rev. 2014, 27, 441–462. [Google Scholar] [CrossRef] [PubMed]
- Matthes-Martin, S.; Feuchtinger, T.; Shaw, P.J.; Engelhard, D.; Hirsch, H.H.; Cordonnier, C.; Ljungman, P. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: Summary of ECIL-4 (2011). Transpl. Infect. Dis. 2012, 14, 555–563. [Google Scholar] [CrossRef] [PubMed]
- Florescu, D.F.; Stohs, E.J. Approach to infection and disease due to adenoviruses in solid organ transplantation. Curr. Opin. Infect. Dis. 2019, 32, 300–306. [Google Scholar] [CrossRef] [PubMed]
- Watcharananan, S.P.; Avery, R.; Ingsathit, A.; Malathum, K.; Chantratita, W.; Mavichak, V.; Chalermsanyakorn, P.; Jirasiritham, S.; Sumethkul, V. Adenovirus disease after kidney transplantation: Course of infection and outcome in relation to blood viral load and immune recovery. Am. J. Transplant. 2011, 11, 1308–1314. [Google Scholar] [CrossRef]
- Yao, Q.Y.; Rickinson, A.B.; Epstein, M.A. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int. J. Cancer 1985, 35, 35–42. [Google Scholar] [CrossRef]
- Kanda, T.; Yajima, M.; Ikuta, K. Epstein-Barr virus strain variation and cancer. Cancer Sci. 2019, 110, 1132–1139. [Google Scholar] [CrossRef]
- Feederle, R.; Klinke, O.; Kutikhin, A.; Poirey, R.; Tsai, M.H.; Delecluse, H.J. Epstein-Barr Virus: From the Detection of Sequence Polymorphisms to the Recognition of Viral Types. Curr. Top. Microbiol. Immunol. 2015, 390, 119–148. [Google Scholar]
- White, R.E.; Rämer, P.C.; Naresh, K.N.; Meixlsperger, S.; Pinaud, L.; Rooney, C.; Savoldo, B.; Coutinho, R.; Bödör, C.; Gribben, J.; et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J. Clin. Investig. 2012, 122, 1487–1502. [Google Scholar] [CrossRef] [PubMed]
- Kelly, G.L.; Milner, A.E.; Baldwin, G.S.; Bell, A.I.; Rickinson, A.B. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA 2006, 103, 14935–14940. [Google Scholar] [CrossRef] [PubMed]
- Lo, A.K.; Dawson, C.W.; Jin, D.Y.; Lo, K.W. The pathological roles of BART miRNAs in nasopharyngeal carcinoma. J. Pathol. 2012, 227, 392–403. [Google Scholar] [CrossRef] [PubMed]
- Murray, P.G.; Young, L.S. Epstein-Barr virus infection: Basis of malignancy and potential for therapy. Expert. Rev. Mol. Med. 2001, 3, 1–20. [Google Scholar] [CrossRef]
- Fukayama, M.; Hayashi, Y.; Iwasaki, Y.; Chong, J.; Ooba, T.; Takizawa, T.; Koike, M.; Mizutani, S.; Miyaki, M.; Hirai, K. Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach. Lab. Investig. 1994, 71, 73–81. [Google Scholar]
- Murphy, G.; Pfeiffer, R.; Camargo, M.C.; Rabkin, C.S. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location [published correction appears in Gastroenterology. 2011 Mar;140(3):1109]. Gastroenterology 2009, 137, 824–833. [Google Scholar] [CrossRef]
- Camargo, M.C.; Kim, W.H.; Chiaravalli, A.M.; Kim, K.; Corvalan, A.H.; Matsuo, K.; Yu, J.; Sung, J.J.Y.; Herrera-Goepfert, R.; Meneses-Gonzalez, F.; et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: An international pooled analysis. Gut 2014, 63, 236–243. [Google Scholar] [CrossRef]
- Törnell, J.; Farzad, S.; Espander-Jansson, A.; Matejka, G.; Isaksson, O.; Rymo, L. Expression of Epstein-Barr nuclear antigen 2 in kidney tubule cells induce tumors in transgenic mice. Oncogene 1996, 12, 1521–1528. [Google Scholar]
- Karaarslan, S.; Şen, N. Investigation of the relationship of Epstein-Barr virus with in situ hybridization in renal-cell carcinomas. Ann. Diagn. Pathol. 2018, 34, 45–49. [Google Scholar] [CrossRef]
- Kang, M.J.; Kim, K.M.; Bae, J.S.; Park, H.S.; Lee, H.; Chung, M.J.; Moon, W.S.; Lee, D.G.; Jang, K.Y. Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma. Transl. Oncol. 2013, 6, 282–289. [Google Scholar] [CrossRef]
- Becker, J.L.; Miller, F.; Nuovo, G.J.; Josepovitz, C.; Schubach, W.H.; Nord, E.P. Epstein-Barr virus infection of renal proximal tubule cells: Possible role in chronic interstitial nephritis. J. Clin. Investig. 1999, 104, 1673–1681. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Zisman, A.; Pantuck, A.J.; Dorey, F.; Chao, D.H.; Gitlitz, B.J.; Moldawer, N.; Lazarovici, D.; deKernion, J.B.; Figlin, R.A.; Belldegrun, A.S. Mathematical model to predict individual survival for patients with renal cell carcinoma. J. Clin. Oncol. 2002, 20, 1368–1374. [Google Scholar] [CrossRef] [PubMed]
- Frank, I.; Blute, M.L.; Cheville, J.C.; Lohse, C.M.; Weaver, A.L.; Zincke, H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J. Urol. 2002, 168, 2395–2400. [Google Scholar] [CrossRef]
- Blazquez-Navarro, A.; Dang-Heine, C.; Wittenbrink, N.; Bauer, C.; Wolk, K.; Sabat, R.; Westhoff, T.H.; Sawitzki, B.; Reinke, P.; Thomusch, O.; et al. BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study. EBioMedicine 2018, 34, 113–121. [Google Scholar] [CrossRef]
- Wijarnpreecha, K.; Nissaisorakarn, P.; Sornprom, S.; Thongprayoon, C.; Thamcharoen, N.; Maneenil, K.; Podboy, A.J.; Cheungpasitporn, W. Hepatitis C infection and renal cell carcinoma: A systematic review and meta-analysis. World J. Gastrointest. Pathophysiol. 2016, 7, 314–319. [Google Scholar] [CrossRef] [PubMed]
Total Number of Positive Cases | Mean Value of the Viral Copy Numbers/uL | |
---|---|---|
EBV | 8 | 198.3 (range 29–829) |
ADV | 3 | 619.7 (range 393–867) |
HSV-1 | 0 | - |
HSV-2 | 0 | - |
CMV | 0 | - |
BKV | 0 | - |
JCV | 0 | - |
Parameter | Non-Infected Patients (Controls) (n = 17) | Infected Patients (ADV or/and EBV Infection) (n = 10) | p-Value (Controls vs. ADV/EBV) | Patients with ADV Infection (n = 3) | p-Value (ADV Positive vs. ADV Negative Patients) | Patients with EBV Infection (n = 8) | p-Value (EBV Positive vs. EBV Negative Patients) |
---|---|---|---|---|---|---|---|
Percentage of women | 41.2% | 30.0% | >0.05 | 66.7% | >0.05 | 25.0% | >0.05 |
Mean age (years) | 57.6 | 71.3 | 0.02 | 73.3 | >0.05 | 69.9 | >0.05 |
Mean BMI (kg/m2) | 24.5 | 27.9 | 0.01 | 26.7 | >0.05 | 28.3 | 0.01 |
Percentage of overweight patients (BMI > 25 kg/m2) | 41.2% | 80.0% | 0.0499 | 66.7% | >0.05 | 87.5% | 0.03 |
Percentage of patients with diabetes | 11.8% | 50.0% | 0.02 | 33.3% | >0.05 | 62.5% | 0.006 |
Percentage of patients with uncontrolled dyslipidemia | 41.2% | 10.0% | >0.05 | 0% | >0.05 | 12.5% | >0.05 |
Median white blood cell count (k/uL) | 8.79 | 6.14 | >0.05 | 10.04 | >0.05 | 5.97 | 0.049 |
Median hemoglobin concentration (g/dL) | 13.8 | 13.1 | >0.05 | 13.3 | >0.05 | 13.1 | >0.05 |
Percentage of abnormal CRP values (>5 mg/L) | 23.5% | 30.0% | >0.05 | 66.7% | >0.05 | 12.5% | >0.05 |
Median creatinine serum concentration (mg/dL) | 0.76 | 1.09 | 0.047 | 1.11 | >0.05 | 1.08 | >0.05 |
Percentage of patients with chronic kidney disease (GFR < 60 mL/min/1.73 m2) | 29.4% | 70.0% | 0.04 | 100% | 0.04 | 62.5% | >0.05 |
Percentage of patients with proteinuria (>30 mg/dL) | 23.5% | 20.0% | >0.05 | 33.3% | >0.05 | 12.5% | >0.05 |
Percentage of patients with hematuria (>3 erythrocytes/HPF) | 41.2% | 50.0% | >0.05 | 66.7% | >0.05 | 50.0% | >0.05 |
Percentage of patients with pyuria (>5 leukocytes/HPF) | 35.3% | 50.0% | >0.05 | 66.7% | >0.05 | 37.5% | >0.05 |
Pathological stage of cancer | pT1a–58.8% pT1b–23.5% pT2a–5.9% pT2b–5.9% pT3a–5.9% pT3b-4–0% missing–0% | pT1a–20% pT1b–20% pT2a–20% pT2b–10% pT3a–20% pT3b-4–0% missing–10% | >0.05 | pT1a–0% pT1b–33.3% pT2a–33.3% pT2b–33.3% pT3a–0% pT3b-4–0% missing–0% | >0.05 | pT1a–25.0% pT1b–12.5% pT2a–12.5% pT2b–12.5% pT3a–25.0% pT3b-4–0% missing–12.5% | >0.05 |
Histological grade of cancer | low grade–76.5% high grade–11.8% missing–11.8% | low grade–40.0% high grade–60.0% missing–0% | 0.01 | low grade–33.3% high grade–66.7% | >0.05 | low grade–37.5% high grade–62.5% | 0.02 |
Histological RCC subtype | clear cell–76.5% papillary–5.9% chromophobe–17.6% other–0% | clear cell–40.0% papillary–50.0% chromophobe–0% other–10.0% | 0.004 | clear cell–33.3% papillary–66.7% chromophobe–0% other–0% | >0.05 | clear cell–50.0% papillary–37.5% chromophobe–0% other–12.5% | >0.05 |
Surgical procedure | partial nephrectomy–47.1% radical nephrectomy–52.9% | partial nephrectomy–40.0% radical nephrectomy–60.0% | >0.05 | partial nephrectomy–33.3% radical nephrectomy–66.7% | >0.05 | partial nephrectomy–37.5% radical nephrectomy–62.5% | >0.05 |
12-month cancer recurrence rate | 12.5% | 10.0% | >0.05 | 0% | >0.05 | 12.5% | >0.05 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kryst, P.; Poletajew, S.; Wyczałkowska-Tomasik, A.; Gonczar, S.; Wysocki, M.; Kapuścińska, R.; Krajewski, W.; Zgliczyński, W.; Pączek, L. Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy. J. Clin. Med. 2020, 9, 3195. https://doi.org/10.3390/jcm9103195
Kryst P, Poletajew S, Wyczałkowska-Tomasik A, Gonczar S, Wysocki M, Kapuścińska R, Krajewski W, Zgliczyński W, Pączek L. Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy. Journal of Clinical Medicine. 2020; 9(10):3195. https://doi.org/10.3390/jcm9103195
Chicago/Turabian StyleKryst, Piotr, Sławomir Poletajew, Aleksandra Wyczałkowska-Tomasik, Stefan Gonczar, Maciej Wysocki, Renata Kapuścińska, Wojciech Krajewski, Wojciech Zgliczyński, and Leszek Pączek. 2020. "Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy" Journal of Clinical Medicine 9, no. 10: 3195. https://doi.org/10.3390/jcm9103195
APA StyleKryst, P., Poletajew, S., Wyczałkowska-Tomasik, A., Gonczar, S., Wysocki, M., Kapuścińska, R., Krajewski, W., Zgliczyński, W., & Pączek, L. (2020). Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy. Journal of Clinical Medicine, 9(10), 3195. https://doi.org/10.3390/jcm9103195